Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Summary

This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Circadian rhythm refers to the internal biological clock in which various processes in the body, including immune cell activity, are controlled by the time of day. Exactly how this works is not fully understood, and the researchers want to see if circadian rhythm control of the immune system can influence response to immunotherapy based on whether it is given in the morning (before 11:00 am) or afternoon (12:00pm). The time of day that immunotherapy is given (morning versus afternoon) may impact the effectiveness in treating patients with advanced or metastatic solid tumors.

Eligibility

Inclusion Criteria:

* Must provide written informed consent before any study-specific procedures or interventions are performed
* Aged ≥ 18 years
* Histologically confirmed advanced/metastatic solid tumor as follows:

  * Non small cell lung cancer (NSCLC) (driver-negative, immune checkpoint inhibitor \[ICI\]-eligible)
  * Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) (platinum-eligible),
  * Renal cell carcinoma (RCC)
  * Biliary-tract cancer (BTC)
  * Hepatocellular carcinoma (HCC)
  * Melanoma
* Planned to receive a Food and Drug Administration (FDA)-approved immune check point inhibitor (e.g., anti-PD-1, anti-PD-L1, anti-CTLA4) regimen for the treatment of their malignancy
* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

Exclusion Criteria:

* Prior ICI-based regimen for treatment of cancer
* Current or prior use of immunosuppressive medication within 28 days before planned standard-of-care immunotherapy infusion, with the exception of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses not exceeding 10 mg/day of prednisone (or equivalent corticosteroid)
* Uncontrolled autoimmune disease requiring immunosuppression
* Active, uncontrolled central nervous system (CNS) metastases

Conditions25

Interventions1

Locations1 site

Find trials near these locations

Related trials

• A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC — Universitaire Ziekenhuizen KU Leuven
• Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenocarcinoma — Fudan University
• Biomarkers in Immunotherapy of Melanoma — Institute of Oncology Ljubljana
• Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer — Hunan Province Tumor Hospital
• Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer — Shanghai Chest Hospital
• IC Plus Low-dose Radiation Plus Cadonilimab in LANPC — Sun Yat-sen University
• ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI — Peking Union Medical College Hospital
• Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer — Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Browse More Trials